We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+14.51%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$997M
AUM Growth
+$109M
(+12%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
11.83%
Top 10 Holdings %
Top 10 Hldgs %
74.49%
Holding
41
New
11
Increased
8
Reduced
8
Closed
10
Avg Time Held Equity + Options
2.9
quarters
Top 10 Avg Time Held Equity + Options
3.7
quarters
Top 20 Avg Time Held Equity + Options
2.5
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
3.7
quarters
Top 20 Avg Time Held Equity only
2.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$37.3M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$24.2M |
| 3 |
Wave Life Sciences
WVE
|
+$22M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$20.4M |
| 5 |
UroGen Pharma
URGN
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$32.8M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$16M |
| 3 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$10.3M |
| 4 |
BeOne Medicines Ltd
ONC
|
+$8.18M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$5.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.61% |
| 2 | Miscellaneous | 6.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Assembly Biosciences
ASMB
$414M
| $145M | 14.51% |
245,264
| – | – |
2014 Q4
13 quarters
|
|
|
2
Ascendis Pharma A/S
ASND
$14.7B
| $119M | 11.96% |
1,822,575
-285,025
| -14% | -$16M |
2016 Q3
6 quarters
|
|
3
Kyntra Bio
KYNB
$23.8M
| $92.5M | 9.28% |
80,097
-1,812
| -2% | -$2.39M |
2014 Q4
13 quarters
|
|
4
Ironwood Pharmaceuticals
IRWD
$593M
| $90.8M | 9.11% |
7,027,386
| – | – |
2015 Q4
9 quarters
|
|
5
Kura Oncology
KURA
$874M
| $70.6M | 7.08% |
3,766,852
| – | – |
2015 Q4
9 quarters
|
|
|
6
Wave Life Sciences
WVE
$619M
| $58.5M | 5.87% |
1,459,072
+522,909
| +56% | +$22M |
2017 Q3
2 quarters
|
|
7
DELISTED
Array Biopharma Inc
ARRY
| $49.8M | 4.99% |
3,049,312
+166,600
| +6% | +$2.67M |
2017 Q3
2 quarters
|
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $45.5M | 4.57% |
4,764,447
-72,100
| -1% | -$777K |
2017 Q1
4 quarters
|
|
9
MacroGenics
MGNX
$218M
| $36.5M | 3.66% |
1,450,606
+309,812
| +27% | +$7.53M |
2017 Q4
1 quarter
|
|
|
10
Arcus Biosciences
RCUS
$2.87B
| $34.5M | 3.46% |
+2,236,387
| New | +$37.3M |
2018 Q1
0 quarters
|
|
|
CELG
11
CALL
DELISTED
Celgene Corp
CELG
| $34.3M | 3.44% |
385,000
-490,000
| -56% | -$47M |
2017 Q4
1 quarter
|
|
12
DELISTED
Apellis Pharmaceuticals
APLS
| $23.4M | 2.34% |
1,056,348
-88,210
| -8% | -$1.73M |
2017 Q4
1 quarter
|
|
|
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $21.3M | 2.14% |
+1,240,470
| New | +$24.2M |
2018 Q1
0 quarters
|
|
|
14
UroGen Pharma
URGN
$1.87B
| $20M | 2.01% |
+402,300
| New | +$20.2M |
2018 Q1
0 quarters
|
|
|
15
CALL
Kyntra Bio
KYNB
$23.8M
| $15M | 1.51% |
13,000
+1,584
| +14% | +$2.09M |
2017 Q4
1 quarter
|
|
|
IMDZ
16
DELISTED
Immune Design Corp.
IMDZ
| $14.4M | 1.45% |
4,437,600
+875,000
| +25% | +$3.1M |
2017 Q4
1 quarter
|
|
17
Agios Pharmaceuticals
AGIO
$1.8B
| $14.1M | 1.42% |
+172,952
| New | +$13.4M |
2018 Q1
0 quarters
|
|
18
Akebia Therapeutics
AKBA
$213M
| $13.6M | 1.36% |
+1,425,000
| New | +$19.9M |
2018 Q1
0 quarters
|
|
|
ACHN
19
DELISTED
Achillion Pharmaceuticals
ACHN
| $13.6M | 1.36% |
3,668,307
+1,827,582
| +99% | +$5.98M |
2017 Q4
1 quarter
|
|
|
DOVA
20
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $11.7M | 1.17% |
+429,729
| New | +$12.9M |
2018 Q1
0 quarters
|
|
21
aTyr Pharma
ATYR
$19.7M
| $10.6M | 1.06% |
279,855
| – | – |
2016 Q4
5 quarters
|
|
22
DBV Technologies S.A. American Depositary Shares
DBVT
$568M
| $10.4M | 1.04% |
+45,000
| New | +$10.6M |
2018 Q1
0 quarters
|
|
|
23
CALL
Ironwood Pharmaceuticals
IRWD
$593M
| $10.3M | 1.03% |
797,353
+200,353
| +34% | +$2.5M |
2017 Q3
2 quarters
|
|
|
24
Protagonist Therapeutics
PTGX
$8.96B
| $9.31M | 0.93% |
+1,083,567
| New | +$20.4M |
2018 Q1
0 quarters
|
|
25
DELISTED
Synlogic
SYBX
| $6.57M | 0.66% |
+46,667
| New | +$7.23M |
2018 Q1
0 quarters
|
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q1 2018 Portfolio in Review
As of Q1 2018, EcoR1 Capital held 41 positions worth $997M, up 12% from $888M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
EcoR1 Capital deployed $118M of net new capital in Q1 2018, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Arcus Biosciences: 2,236,387 shares worth $34.5M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 84% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $16M trimmed.
- EcoR1 Capital's largest Q1 2018 buy was Arcus Biosciences: 2,236,387 shares worth $34.5M.
- EcoR1 Capital added most to Wave Life Sciences in Q1 2018, an estimated $22M increase.
- EcoR1 Capital's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $16M.
- EcoR1 Capital fully exited MyoKardia, Inc. Common Stock in Q1 2018, selling an estimated $32.8M.
- EcoR1 Capital's ten largest holdings make up 74% of its $997M portfolio in Q1 2018.
- EcoR1 Capital opened 11 new positions and closed 10 in Q1 2018.
- EcoR1 Capital's portfolio value rose 12% quarter-over-quarter to $997M.
Based on EcoR1 Capital's 13F filing for Q1 2018, filed 15 May 2018.